CTI BioPharma (CTIC) – Hot Corp. News
-
CTI BioPharma (CTIC) Acquired by Sobi for $9.10/sh or $1.7B Cash
-
CTI BioPharma (CTIC) Phase III Trial Evaluating PFS of PIXUVRI Combined with Rituximab in Patients with Aggressive B-cell NHL Did Not Meet Primary Endpoint
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CTIC Stock Lookup